A spinal fluid test may help find cancer that has spread to the brain lining
Original title: Growth Differentiation Factor 15 as a Cerebrospinal Fluid Biomarker for the Diagnosis and Prognosis of Leptomeningeal Metastasis.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
It was studied in people, but it is a test doctors cannot order yet.
The short version
A protein in spinal fluid was much higher when cancer had spread to the lining of the brain.
What was studied. Researchers measured two proteins in spinal fluid from people with lung or breast cancer. They used 726 spinal fluid samples in the lung group and 83 in the breast cancer group.
What they found. The protein GDF15 was more than 25 times higher when lung cancer had spread to the brain lining. It also helped tell these patients apart from people with other brain tumors. People with higher GDF15 levels lived a shorter time.
What this means, and what it doesn't
What it could mean: This is a test, not a treatment. It may one day help doctors spot this kind of spread sooner. Finding it sooner could help a care team plan next steps.
What it doesn't mean: This does not mean a new treatment is here. It is not a cure and it does not treat cancer. The work was done on stored spinal fluid samples. The test is not part of normal care, and your doctor cannot order it today.
Source: PubMed, September 22, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.